EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anticancer drug therapy for anaplastic thyroid cancer

Naomi Kiyota iD, Taiji Koyama, Iwao Sugitani

European Thyroid Journal · 01.04.2025 · 14 (2)

DOI: 10.1530/etj-24-0287 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Thyroid Journal, online erschienen am 31.03.2025. Verfasst von Naomi Kiyota und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid cancer is one of the rarest subtypes of thyroid cancer, accounting for only 1–2% of all thyroid cancer cases. It is also one of the most aggressive: prognosis remains dismal and the disease-specific mortality rate is close to 100%. This rarity has markedly limited the availability of prospective trial results, and no standard chemotherapeutic option for unresectable or metastatic anaplastic thyroid cancer has yet been established. Nevertheless, combination therapy with a BRAF inhibitor and MEK inhibitor has shown encouraging efficacy in patients with BRAF V600E-mutated anaplastic thyroid cancer. Other novel treatments such as immune checkpoint inhibitors have also shown promising results. Owing to these therapeutic advances, the prognosis of anaplastic thyroid cancer appears to be gradually improving. However, further development of novel treatments for this rare malignancy requires the development of substantial infrastructure for international collaborative study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsAntineoplastic AgentsHumansProto-Oncogene Proteins B-rafProtein Kinase InhibitorsImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BRAF V600Eanaplastic thyroid canceranticancer treatmentchemotherapyimmune checkpoint inhibitormolecular targeted agent

Substanzen

Proto-Oncogene Proteins B-rafAntineoplastic AgentsProtein Kinase InhibitorsImmune Checkpoint InhibitorsBRAF protein, human

Autor:innen und Institutionen

ORCID-Profile: Naomi Kiyota

Zitieren

APA

Kiyota, N., Koyama, T., & Sugitani, I. (2025). Anticancer drug therapy for anaplastic thyroid cancer. European Thyroid Journal, 14(2). https://doi.org/10.1530/etj-24-0287

Vancouver

Kiyota N, Koyama T, Sugitani I. Anticancer drug therapy for anaplastic thyroid cancer. European Thyroid Journal. 2025;14(2). doi:10.1530/etj-24-0287

BibTeX
@article{Kiyota2025,
  author = {Kiyota, Naomi and Koyama, Taiji and Sugitani, Iwao},
  title = {Anticancer drug therapy for anaplastic thyroid cancer},
  journal = {European Thyroid Journal},
  year = {2025},
  volume = {14},
  number = {2},
  doi = {10.1530/etj-24-0287}
}
Kostenlos starten →